Long Focus Capital Management, LLC Vincerx Pharma, Inc. Transaction History

Long Focus Capital Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.88 - $1.9 $278,254 - $600,776	-316,198 Reduced 22.35%	1,098,753 $1.43 Million
Q1 2023 May 17, 2023	BUY	$0.9 - $1.51 $782,639 - $1.31 Million	869,599 Added 159.46%	1,414,951 $1.47 Million
Q1 2023 May 12, 2023	SELL	$0.9 - $1.51 $782,639 - $1.31 Million	-869,599 Reduced 61.46%	545,352 $567,000
Q4 2022 Feb 13, 2023	BUY	$0.64 - $1.32 $226,205 - $466,548	353,446 Added 33.3%	1,414,951 $1.44 Million
Q3 2022 Nov 14, 2022	BUY	$0.0 - $1.72 $0 - $140,188	81,505 Added 8.32%	1,061,505 $1.47 Million
Q2 2022 Aug 12, 2022	BUY	$0.0 - $0.0 $0 - $0	549,800 Added 127.8%	980,000 $1.29 Million
Q1 2022 May 13, 2022	BUY	$0.0 - $0.0 $0 - $0	289,997 Added 206.84%	430,200 $1.72 Million
Q4 2021 Feb 14, 2022	BUY	$0.0 - $0.0 $0 - $0	140,203 New	140,203 $1.43 Million

11M

Ticker VINC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,189,800
Market Cap $4.03M
Description
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candid...

Get notified when there are updates to the investment portfolio of Long Focus Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Long Focus Capital Management, LLC with notifications on news.